• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Vyvanse (lisdexamfetamine dimesylate) 20mg, 30mg, 40mg, 50mg, 60mg, 70mg capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- May 2009


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View



Clinical Studies Experience
  • In addition, adverse reactions observed at a rate of less than 2% included decreased libido and erectile dysfunction.
Postmarketing Reports
  • Eye Disorders- vision blurred
  • Nervous System Disorder- psychotic episodes, mania, hallucination, aggression